Abbott Receives CE Mark for Dual-Ablation Catheter

Abbott has received a CE mark in Europe for its TactiFlex Duo catheter, designed to treat atrial fibrillation and other heart arrhythmias. The device delivers both radiofrequency and pulsed field ablation (PFA) energy, allowing physicians to switch between methods during a procedure depending on patient needs and anatomy.

PFA uses high-energy electrical pulses to create scar tissue, reducing risks to surrounding tissue and shortening procedure times compared with traditional heat-based radiofrequency ablation. Abbott’s TactiFlex Duo CE mark was supported by clinical trials in the EU, UK, and Australia, demonstrating safety and effectiveness.

The device is aimed at complex cases, including patients with long-standing AFib, heart failure, ventricular arrhythmias, or previous failed ablations. Abbott also received FDA breakthrough device designation last year for PFA treatment of ventricular tachycardia and is conducting U.S. clinical trials for AFib.

20-01-2026